DarshanTalks Podcast

Send us Fan Mail

For decades, biotech M&A followed a familiar script. Patents drove value. Molecules closed deals.

That script is breaking.

In today’s precision medicine transactions, the real asset is data. Longitudinal patient records, real-world evidence, and genomic datasets are now central to valuation. But unlike traditional IP, data comes with strings attached. Privacy laws, patient consent, and transfer restrictions can quietly determine whether that data is an asset or a liability.

In this episode of KLF Deep Dive, we explore why clinical data is being treated as the new IP in biotech M&A, how weak consent frameworks can destroy deal value, and what acquirers should be asking during diligence before it’s too late.

If you work in biotech, pharma, corporate development, or private equity, this episode breaks down a risk that is reshaping how deals get priced and structured.

Listen in, and reach out if this issue is sitting inside one of your transactions.

Episode Highlights

• Why patents alone no longer drive biotech valuations
• How precision medicine changed the M&A playbook
• Clinical data as a regulated asset
• Patient consent and data transfer risks
• When valuable datasets become compliance liabilities
• What smart buyers are doing differently in diligence

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Staffing and training are not just operational issues. They are inspection risks. In this episode, we break down what sponsors and regulators actually expect when it comes to site staff training. Competent staff is not enough if training is not documented. We walk through common failure points seen during FDA inspections, including missing GCP documentation, unclear staff roles, and poor escalation processes. We also discuss how structured SOPs, training logs, and clear contracts with coordinators and sub-investigators help demonstrate a real culture of compliance. The goal is simple. When sponsors or the FDA review your site, your records should tell a clear, defensible story.

Key Topics Covered

• GCP training and documentation expectations
• Why undocumented training creates inspection risk
• Common staffing failures seen during FDA inspections
• Training SOPs and staff training logs
• Defining roles and liability in staff contracts
• Managing protocol deviations and escalation paths
• Demonstrating a culture of compliance at the site level

Who This Is For

• Clinical trial sites
• Sponsors and CROs
• Principal Investigators
• Study coordinators
• Clinical operations leaders

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

 Early termination by a sponsor can leave a clinical research site holding the bill for prep work, fees, and staffing. In this episode, Darshan explains the contract language every site should insist on to stay protected. He covers guaranteed payment for all work performed up to the termination date, reimbursement for non-cancelable expenses like IRB fees and advertising, and why a wind-down clause is essential for chart reviews, final visits, and data queries. He also explores when minimum payments or upfront funds are realistic to request. Protecting these terms upfront keeps an unexpected sponsor exit from destabilizing your operations. If you have question, Call 302.252.6959, click www.kulkarnilawfirm.com , or email [email protected]. 

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Your skincare product may look like a cosmetic, but one wrong claim can legally turn it into an unapproved drug.

In this episode of KLF Deep Dive, we break down the exact words, phrases, and influencer mistakes that push cosmetic brands straight into FDA drug territory. Anti-inflammatory claims. Acne treatment language. Collagen rebuilding promises. Detox buzzwords. These are not harmless marketing fluff. They are regulatory landmines.

We explain how the FDA actually classifies products, why intent does not matter, how influencers can sink your brand, and what cosmetic companies should do right now to stay compliant.

If you work in beauty, skincare, or wellness marketing, this episode can save your next launch.

If compliance, enforcement, or deals matter to your business, subscribe to KLF Deep Dive.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Influencers can boost visibility fast, but they also create real regulatory exposure if they go off script. The FTC requires influencers to clearly disclose any material connection to your brand, and the wrong claim in a single post can trigger enforcement or lawsuits. In this episode, I explain how I build influencer contracts with mandatory disclosure language, claim restrictions, and takedown rights. I also describe how I design monitoring systems so brands can review influencer content before or after posting, and how I create influencer playbooks to keep everyone aligned. When done right, influencer marketing becomes a compliant and scalable growth channel. Call, click, or email if you need help. 

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

 A lot of brands start with harmless wellness promises like better mood, more energy, or improved sleep. As the business grows, though, marketing often becomes bolder, and that’s where risk creeps in. The FDA steps in when your claims imply treating or preventing a disease, which can flip your product into drug or device territory. The FTC expects every wellness claim to be truthful and supported by real evidence. In this episode, I explain how I review labels, websites, and social content, map each claim to the right regulatory bucket, and draft compliant alternatives that keep your marketing appealing without triggering expensive oversight. I also build claim checklists to help teams avoid drift in the future. Call, click, or email if you need support. 

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

 A knee implant meant to restore mobility. A surgeon secretly collecting international trips and consulting checks. A device company accused of selling a product they allegedly knew would fail. This episode breaks down the Aesculap case, the $38.5M settlement, and what it teaches us about kickbacks, forged FDA documents, and the catastrophic cost of weak compliance controls. If your team works in pharma, med-tech, or clinical research, you don’t want to miss this one. 

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

In this episode of DarshanTalks, you dive into what U.S. Food and Drug Administration (FDA) inspectors will demand when they show up on-site. You walk through the five critical documents every life-sciences or pharma company should have ready, because without them, an inspection can become a deal-breaker fast.

You stress that compliance isn’t just paperwork; it’s the backbone of long-term viability. A weak document trail, sloppy record-keeping, or missing records can lead to penalties, regulatory exposure, or even shutdowns. Tight compliance and strong documentation aren’t optional. They’re deal insurance.

The episode gives concrete guidance on what to have in place before regulators knock. It’s essential listening for executives, compliance officers, and M&A advisors in biotech, pharma, and medical device businesses.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

 Beauty brands hit trouble when they forget they’re dealing with two regulators, not one. The FDA controls how cosmetics are labeled and when a claim crosses into drug territory. The FTC cares about whether your marketing is truthful, especially online, and expects competent and reliable scientific evidence for every objective claim you make. Say “clinically proven” without real clinical data and both agencies may come knocking. In this quick breakdown, I explain how to align your claims so they excite consumers while staying compliant. Protect your brand, limit risk, and build trust. Call, click, or email if you need help. 

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Clinical research sites lose money when sponsor contracts skip the real costs of running a study. In this episode, Darshan breaks down how to protect your site by building a detailed, task-based budget instead of accepting broad lump-sum payments. He explains why every activity needs to be itemized, from screen failures and pharmacy prep to coordinator overtime and regulatory time. You’ll hear practical tips on tying costs to CPT codes, adding overhead where possible, and making sure you can bill for out-of-scope work like unexpected SAEs and follow-up. He also highlights a commonly overlooked issue: what gets paid when the contract ends. Chart reviews, data queries, and PI closeout time all need clear language. If it’s not written down, it won’t get paid. This quick guide helps sites negotiate smarter and stay financially healthy. Call 302.252.6959 if you have questions, or email [email protected]

Support the show

www.kulkarnilawfirm.com